Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)

NCT02049138 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02049138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02049138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
January 24, 2014
Completion date
July 29, 2021
Enrollment
493 (actual)
Sites
124

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis